With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
DOCU — frequently asked questions
Is DocuSign, Inc. overvalued?
In our latest published analysis dated 2026-05-10, DOCU looks meaningfully overvalued. The price recorded at analysis is USD 47.9 versus our fair value of USD 28.6; the high endpoint is presented separately as potential value of USD 36.5. That implies roughly 40.3% downside to fair value at that date.
Our latest published report, analyzed 2026-05-10, gives DOCU a fair value of USD 28.6 and a potential value of USD 36.5. The conclusion is triangulated across multiple valuation models and weighted by reliability for DocuSign, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy DOCU now?
Our latest published rating for DOCU, analyzed 2026-05-10, is Sell. DocuSign, Inc. looks meaningfully overvalued at the analysis-date price of USD 47.9 versus fair value of USD 28.6; potential value is USD 36.5. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for DOCU?
The dedicated bear-case section in our report analyzed 2026-05-10 documents DocuSign, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is DOCU's rating?
Our latest published rating for DOCU, analyzed 2026-05-10, is Sell, with a published moat assessment of 6.5/10 (narrow). It reflects our fair value of USD 28.6, the potential value of USD 36.5, and the price recorded at analysis (USD 47.9).
Bull: Successful expansion of Intelligent Agreement Management (IAM) accelerates revenue back to double-digits, while cost discipline drops the high incremental gross margins straight to the bottom line.
Main risk
Severe Pricing Compression: Enterprise customers aggressively negotiate e-signature renewals as bundled alternatives like Adobe become good enough, collapsing gross margins.
DocuSign is a mature software compounder generating exceptional free cash flow and maintaining dominant market share in e-signature. However, heavy stock-based compensation and decelerating top-line growth present valuation headwinds. The base case assumes steady, low-growth cash generation with gradual GAAP margin improvement.
DocuSign is a mature software compounder generating exceptional free cash flow and maintaining dominant market share in e-signature. However, heavy stock-based compensation and decelerating top-line growth present valuation headwinds. The base case assumes steady, low-growth cash generation with gradual GAAP margin improvement.
Switching Costs
Switching Costs
Network Effects
Network Effects
Cycle upside
Enterprise digitization expands beyond simple signatures into full contract lifecycle management.
House recommendation
Sell. Market pricing misprices structural growth deceleration and systemic SBCdilution.
Company overview
DocuSign, Inc. provides electronic signature solution in the United States and internationally. The company offers AI-powered intelligent agreement management (IAM) platform to optimize the gain intelligence and automation across the entire agreement lifecycle; and provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; and Document Generation streamlines the process of generating new, custom agreements. It also provides Identify, a signer-identification option for checking government-issued IDs; Standards-Based Signatures, which support signatures that involve digital certificates; Monitor that uses advanced analytics; Notary which enables notaries public to conduct remote online notarization transactions; and Web Forms. In addition, the company offers Real Estate for eSignature that provides a way for brokers and agents to manage the entire real estate transaction digitally. eSignature and CLM are Federal Risk and Authorization Management Program (FedRAMP), an authorized version of DocuSign eSignature for U.S. federal government agencies; and life sciences modules that support compliance with the electronic signature practices. The company sells its products through direct and partner-assisted sales, and digital self-service purchasing. DocuSign, Inc. was incorporated in 2003 and is headquartered in San Francisco, California.
A rapid acceleration in e-signature commoditization drives intense pricing pressure, collapsing top-line growth to near zero while GAAP margins remain structurally impaired by relentless stock-based compensationdilution.
If IAM shows material billings acceleration, upside exists to mid-$30s. If core e-signature churns or pricing collapses, expect a re-rating into the low $20s.
In-line
Hold
Trigger: In-line results
If IAM shows material billings acceleration, upside exists to mid-$30s. If core e-signature churns or pricing collapses, expect a re-rating into the low $20s.
Miss
Reassess
Trigger: Downside surprise
If IAM shows material billings acceleration, upside exists to mid-$30s. If core e-signature churns or pricing collapses, expect a re-rating into the low $20s.
If IAM shows material billings acceleration, upside exists to mid-$30s. If core e-signature churns or pricing collapses, expect a re-rating into the low $20s.
Mature software companies pivot from aggressive growth investments to heavy cash return, attempting to outpace SBCdilution via share repurchases.
Bull cycle
Enterprise digitization expands beyond simple signatures into full contract lifecycle management.
Bear cycle
Software budget consolidation leads IT buyers to drop best-of-breed signature tools for bundled suite options.
Positioning
Mature software companies pivot from aggressive growth investments to heavy cash return, attempting to outpace SBCdilution via share repurchases.
§11 Position management
Sizing
Avoid. The synthesized fair value of $28.60 represents a material 52.5% discount to the street target.
Risk
Current holders should consider rotating out at current levels (~$47.90) as market pricing severely miscalculates the structural deceleration.
Entry tranches
Level
Action
Why
Current / pullbacks
Requires a substantial pullback into the low $20s to provide a sufficient margin of safety against structural .
§12 Investor perspectives
Bull view
Buy
Upside case depends on the report valuation range and named growth catalysts.
Base view
Sell
The private calibration street target of $60.16 anchors heavily on non-GAAP EPS that ignores the 19% of revenue paid in SBC.
§14 Final recommendation
Action
Sell
DOCU is rated Sell at $47.90 versus the reconciled fair value midpoint of $28.60, implying -40.29% upside/downside.
At $47.90, the stock is measured against the final $28.60 midpoint and -40.29% upside/downside, so new capital should respect the report margin-of-safety discipline.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Commoditization of e-signatures leads to pricing pressure, while persistent high SBC continually dilutes shareholders, offsetting the strong free cash flow generation.
Ways this thesis can break
Severe Pricing Compression
Medium
Enterprise customers aggressively negotiate e-signature renewals as bundled alternatives like Adobe become good enough, collapsing gross margins.
FV impact
-30%
Trigger
12-24 months
IAM Adoption Failure
High
The Intelligent Agreement Management platform fails to gain traction among enterprise clients, limiting growth entirely to the saturated core e-signature market.
Operational margin contraction indicates a loss of operating leverage, where competitive price discounting and rising administrative overhead outpace software revenue expansion.
Current:9.3% for the period ended 2026-01-31
Alert ifGAAP operating margin contracts year-over-year across any fiscal year
04
Annual Billings Growth Rate
Negative billings growth reflects severe forward bookings contraction as e-signature software commoditizes, leading inevitably to deferred revenue depletion and subsequent top-line revenue declines.
Current:8.2% revenue growth for the period ended 2026-01-31
Alert ifTotal billings growth falls below 0.0% across any trailing four-quarter window
Weakening operating cash generation relative to accounting profit points to uncollected enterprise receivables and unfavorable working capital movements, eliminating the primary cash flow support for valuation.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Successful expansion of Intelligent Agreement Management (IAM) accelerates revenue back to double-digits, while cost discipline drops the high incremental gross margins straight to the bottom line.
DocuSign is a mature software compounder generating exceptional free cash flow and maintaining dominant market share in e-signature. However, heavy stock-based compensation and decelerating top-line growth present valuation headwinds. The base case assumes steady, low-growth cash generation with gradual GAAP margin improvement.
Current$622M non-cash SBC against $309M GAAP net income as of 2026-05-10
Why it matters
Warning level: Stock-based compensation exceeds 20.0% of total revenue over any trailing twelve-month period. Excessive non-cash share issuance dilutes existing equity holders and prevents free cash flow generation from translating into GAAP per-share earnings growth.
Warning level: GAAP operating margin contracts year-over-year across any fiscal year. Operational margin contraction indicates a loss of operating leverage, where competitive price discounting and rising administrative overhead outpace software revenue expansion.
04
Metric:
Annual Billings Growth Rate
Current8.2% revenue growth for the period ended 2026-01-31
Why it matters
Warning level: Total billings growth falls below 0.0% across any trailing four-quarter window. Negative billings growth reflects severe forward bookings contraction as e-signature software commoditizes, leading inevitably to deferred revenue depletion and subsequent top-line revenue declines.
Warning level: Operating cash flow to net income drops below 1.000 over any trailing twelve-month period. Weakening operating cash generation relative to accounting profit points to uncollected enterprise receivables and unfavorable working capital movements, eliminating the primary cash flow support for valuation.
